Cargando…
A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease which continues to carry an unacceptably high mortality and morbidity. The nitric oxide (NO) pathway has been implicated in the pathophysiology and progression of the disease. Its extremely short half-life and systemic effect...
Autores principales: | Mohamed, Nura A., Ahmetaj-Shala, Blerina, Duluc, Lucie, Mackenzie, Louise S., Kirkby, Nicholas S., Reed, Daniel M., Lickiss, Paul D., Davies, Robert P., Freeman, Gemma R., Wojciak-Stothard, Beata, Chester, Adrian H., El-Sherbiny, Ibrahim M., Mitchell, Jane A., Yacoub, Magdi H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830862/ https://www.ncbi.nlm.nih.gov/pubmed/26960567 http://dx.doi.org/10.1007/s12265-016-9684-2 |
Ejemplares similares
-
Role of prostacyclin in pulmonary hypertension
por: Mitchell, Jane A., et al.
Publicado: (2014) -
Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy
por: Mohamed, Nura A., et al.
Publicado: (2017) -
Studies on metal–organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension
por: Mohamed, Nura A., et al.
Publicado: (2021) -
Tipifarnib prevents development of hypoxia-induced pulmonary hypertension
por: Duluc, Lucie, et al.
Publicado: (2017) -
Cardiorenal Tissues Express SARS-CoV-2 Entry Genes and Basigin (BSG/CD147) Increases With Age in Endothelial Cells
por: Ahmetaj-Shala, Blerina, et al.
Publicado: (2020)